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Abstract 
Background: Although anti‑retroviral therapy has generally improved the survival of HIV infected patients in many 
developing countries including Ghana, specific socio‑demographic factors could still influence outcome of treatment. 
This study was designed to identify patient‑specific factors that could influence the immune recovery of absolute CD4 
count in HIV infected patients.
Findings: Hospital records were extracted from two health facilities in Ghana. The impact of socio‑demographic fac‑
tors type of ART and baseline category of CD4 counts were assessed at six monthly interval using robust linear mixed 
models.
Results: A total of 214 follow up records were reviewed at Komfo Anokye Teaching Hospital (KATH) and the Kumasi 
South Hospital (KSH). One hundred (46.7 %) were from KATH and 114 (53.3 %) were from KSH. There was a general 
increase in the level of CD4 counts with time, however this increase significantly slowed down with subsequent 
reviews (p < 0.001). On the average the rate of CD4 count recovery slowed down by 43.6 cells/µl for every 6 months 
of follow up (SE = 7.69; p < 0.001). Similarly the recovery of CD4 counts in subjects with an initial high baseline CD4 
counts decreased by 192.6 cells/µl (SD error = 42.3, p value ≤0.001). All other variables were not significantly associ‑
ated with recovery of CD4 counts.
Conclusion: Our study has demonstrated the well‑known phenomenon of CD4 counts increasing after administra‑
tion of ARTs. CD4 counts increased more rapidly in those with relatively lower initial counts, catching up with those 
with high CD4 count by 2 years post treatment.
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Background
The introduction of highly active antiretroviral therapy 
(HAART) has slowed down the disease progression of 
HIV infected patients in both developed and developing 
countries [1, 2]. Therapeutic success, however, increas-
ingly depends on thorough understanding of the patho-
genesis of HIV disease and familiarity with when and 
how to use the numerous and more effective drugs avail-
able to treat HIV infection.
Decisions regarding initiation and/or changes in anti-
retroviral therapy (ART) are guided by monitoring the 
laboratory parameters of plasma HIV RNA (viral load) 
and CD4+ T cell count in addition to the patient’s clini-
cal condition [3–5]. Results of these laboratory tests 
provide clinicians with key information regarding immu-
nologic status of the patient and their risk for disease 
progression to acquired immunodeficiency syndrome 
(AIDS). In addition, the demonstrations of the prognos-
tic value of the CD4 cell count and the plasma viral load 
were of major importance in the development of thera-
peutic strategies.
Some laboratories in resource-constrained countries, 
however, cannot afford to perform laboratory-moni-
toring tests of HIV-viral load in particular. As such the 
World Health Organization (WHO) has advocated CD4 
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cell count as the basis for monitoring ART in resources-
limited settings [6].
The recovery of CD4 T lymphocytes in treated per-
sons is usually accompanied by enhanced T-lymphocyte 
responses to antigens and mitogens, providing adequate 
protection against opportunistic infections. It’s utility, 
however, is influenced by a number of factors including 
immunological and host specific factors such as age, gen-
der, educational level, socio-economic status etc., [7–9]. 
The reasons for these different responses remain largely 
unknown although suggestions have been made that dif-
ferences in residual thymic function may play a role [10]. 
Other factors such as the degree of immunodeficiency 
before initiation of HAART, residual viral activity and 
viral co-infections such as hepatitis B or C have also been 
implicated [11, 12]. While the specific factors underlying 
the long-term recovery of CD4 T lymphocytes deserves 
particular attention because of its major clinical signifi-
cance, only few studies have addressed this issue. Infor-
mation on the socio-demographic and economic factors 
influencing recovery of CD4 counts among HIV infected 
patients is limited in many developing countries includ-
ing Ghana. This study was therefore designed to deter-
mine the association of patient-specific factors such as 
age, gender, socio-economic status and baseline value to 
four sequential values of absolute CD4 T-cells of HIV-
infected patients on ART at the Komfo Anokye Teaching 




This was a retrospective study carried out between Janu-
ary 2008 and December 2009. The study was carried out 
at the Serology Units of the Clinical Microbiology labora-
tory at KATH and the KSH respectively, after appropriate 
permission has been sought from the respective hospi-
tal authorities. The laboratories undertake an external 
quality assurance system in conjunction with the South 
Africa Quality Assurance company (AFRQUAS) through 
the National AIDS Control Programme. KATH is the 
teaching hospital of the Kwame Nkrumah University of 
Science and Technology (KNUST) and the only tertiary 
health institution in the Ashanti region. It is thus the 
main referral hospital serving predominantly the central 
and northern sectors of Ghana including the Ashanti, 
Brong Ahafo, Northern, Upper East and Upper West 
regions. KSH on the other hand is a relatively smaller 
hospital which attends to patients mostly from deprived 
areas of the Ashanti region.
Study populations were children 10  years and above 
and adult HIV infected patients enrolled on ART pro-
gramme at the HIV clinic of KATH and the KSH. The 
first-line treatment available at the two facilities within 
the period of the study were two nucleoside reverse tran-
scriptase inhibitor drugs (NRTI) being azidovudine (d4T) 
and lamivudine (3TC) plus a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) drugs being nevirapine 
(NVP) or efavirenz (EFV). Protease inhibitor drugs such 
as Nelfinavir (NFV), Kaletra or Indinavir were also used 
in combination with the nucleoside based reverse tran-
scriptase inhibitor drugs. Absolute CD4+ T-lympho-
cyte were quantified using the FACSCount (BD, USA), 
according to the manufacturer’s instructions.
Data collection
Patients’ data were collected by reviewing their hospital 
records for information such as age, sex, marital status, 
educational level, economic status, religion, availability 
of family support. Their HIV results and type were noted 
as well as their CD4 count at both pre- and post-therapy. 
CD4 counts were recorded before initiation of HAART 
and at four time points (6, 12, 18 and 24  months) after 
initiation of HAART. We used a bound of plus or minus 
1  week for data collection at the time points. We also 
excluded children less than 10  years because their data 
were not readily available as at the time of conducting 
this research. Data were double entered in spreadsheet 
database prepared with Microsoft® Excel. It was then 
compared and cleaned for abnormal wrongful entries.
Ethical approval
The protocol for this study was approved by the Com-
mittee for Human Research, Publication and Ethics of 
the Komfo Anokye Teaching Hospital (KATH) and the 
School of Medical Sciences, KNUST, Kumasi, Ashanti 
region, Ghana. Permission was also sought from the 
study sites before the data was collected.
Statistical analysis
Data analysis was performed using R statistical software 
version 3.0.2 [13]. Continuous variables were expressed 
as medians with their inter-quartile ranges (IQR) and cat-
egorical variables were expressed as percentages.
For the purpose of analysis, economic status of sub-
jects was categorised based on their annual income into 
low income earners (≤$800), middle income (>$800–
US$2000) earners and high income earners (>$2000). 
These classifications were made based on the occupation 
of subjects and the US dollar exchanged rates existing in 
Ghana between the years January 2008 and December 
2009. Similarly, the ages of subjects were classified into 
10–30, 31–40 and 41–72  years to allow for equivalent 
distribution.
To determine the overall trajectory of absolute com-
pared to the baseline counts, we categorized the baseline 
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CD4 counts into low and high. Subjects with baseline 
CD4 counts below 250  cells/µl were categorized as low 
and those with counts above 250 were categorized high. 
The 250 cut off value was based on the national treatment 
policy adopted by Ghana (2004).
The effects of socio-demographic and economic factors 
on the recovery of CD4 counts were assessed using linear 
mixed models. Linear mixed model was used to analyse 
the data because these models are relatively robust to 
missing values and assume that values missing at random 
are only dependent on the observed data and not unob-
served data [14]. Before using the mixed models, we first 
evaluated whether missing values were missing at ran-
dom. We did this by creating a ‘missing’ indicator vari-
able as the outcome variable and then used Chi-square, 
Student’s t test and logistic regression to evaluate its 
association with all socio-demographic variables.
The mixed model was defined using the time point 
changes in CD4 counts as dependent variable and the 
socio-demographic and economic variables as fixed 
effects. Each fixed effect factor was tested indepen-
dently along with subject specific random effect while 
controlling for time of follow up. The independent fac-
tors associated with CD4 count recovery were deter-
mined by using significant variables derived from the 
univariate analysis along with other variables of interest 
as fixed effects in a full multivariate model. The model-
ling was done first using subject specific random effect 
and then time specific random effect. The two models 
were compared using analysis of variance and the best 
model determined by choosing the one with lowest 
Akaike Information Criterion (AIC). All results of the 
modelling were expressed as the parameter estimate and 
their standard error. For all analysis, a two-sided p value 
of less than 0.05 was considered significant. The NLME 




A total of 214 patients record were reviewed at KATH 
and the KSH. One hundred (46.7  %) were from KATH 
and 114 (53.3 %) were from KSH. The median age of all 
study subjects was 37 years (IQR: 32–43). The number of 
females (159; 74.3 %, 95 %CI 67.9–80.0) was higher than 
males and most of them were from the KSH. Primary 
education was the highest (126; 63.6  %) with majority 
from the KSH. Sixteen (8.1  %) subjects were illiterates. 
Most of the subjects were in the low economic range 
(157; 80.1 %) with KSH having the highest. Most subjects 
also depended on their relatives as the only means of sup-
port. Only 29 subjects (14.7 %) could support themselves. 
Table 1 describes the characteristics of the study subjects.
Longitudinal changes in absolute CD4 counts
The median CD4 count before administration of 
HAART was 212  cells/µl (IQR  =  93.5–335.5). The 
median absolute counts increased significantly 
(p  <  0.001) to 308.5  cells/µl (IQR  =  196–457.5) 
after 6  months and reached a value of 350  cells/µl 
(IQR  =  196–457.5) after 1  year. The median counts 
reached a peaked value of 453 cells/µl (IQR = 298–616) 
after 24  months of follow up. Figure  1 describes the 
medians and interquartile ranges of all CD4 counts at 
the different time points.
The median CD4 count before administra-
tion of HAART for age group 10–30 was 266  cells/
µl (IQR  =  115–463). This increased to 384  cells/µl 
(IQR = 255.5–540.0) after 6 months and then decreased 
to 332  cells/µl (IQR =  248.5–535.5) after 1  year of fol-
low up. Subjects who were in age groups 31–40 and 
41–80  years had similar CD4 counts of 210.5 (82.3–
323.0) and 201 (120–311) respectively before adminis-
tration of HAART. After 6 months, the counts increased 
to 309 (181.25–453.0) and 277.0 (195–442) respectively. 
These counts increased marginally after 1 year of follow 
up and then levelled off. Figure 2a describes the median 
absolute CD4 counts of age groups at the various time 
points of follow ups.
Table 1 Baseline characteristics of study subjects
Health institution, n (%)
KATH SGH Total
Gender Female 67 (67.0 %) 92 (80.7) 159 (74.3)
Age (median, IQR) 38 (33–45) 35 (31–42) 37 (32–43)
Educational levels
 None 16 (19.0) 0 (0.0) 16 (8.1)
 Primary 49 (58.3) 77 (67.5) 126 (63.6)
 Secondary 11 (13.1) 7 (6.1) 18 (9.1)
 Tertiary 8 (9.5) 30 (26.3) 38 (19.2)
Economic status
 Low 71 (86.6) 86 (75.4) 157 (80.1)
 Medium 10 (12.2) 22 (19.3) 32 (16.3)
 High 1 (1.2) 6 (5.3) 7 (3.6)
Primary caregiver
 Spouse 21 (25) 43 (37.7) 64 (32.3)
 Relatives 34 (40.5) 57 (50) 91 (46)
 Self 25 (29.8) 4 (3.5) 29 (14.6)




39 (50.6) 21 (18.4) 60 (31.4)
 Azidovudine/lamivudine + PI 0 (0) 18 (15.8) 18 (9.4)
 Stavudine/lamivudine + NNRTI 21 (27.3) 74 (64.9) 95 (49.7)
 Others 17 (22.1) 1 (0.9) 18 (9.4)
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The median absolute CD4 counts of females were 
generally higher than males (Fig.  2b). The CD4 counts 
before administration of HAART were 216  cells/µl 
(IQR  =  106.0–347.5) for females and 197.0  cells/µl 
(IQR = 72.0–285.5) for males. After 6 months of HAART 
administration, the counts increased sharply to 343 
(200–498.5) and 278 (186.5–425.0) for females and males 
respectively. These increments continued with females 
showing higher counts than males.
We also compared the CD4 counts recorded at KATH 
and the KSH. The median CD4 counts before administra-
tion of HAART were 239 cells/µl (IQR = 141.25–401.5) 
and 192.5  cells/µl (IQR =  83–286) for KATH and KSH 
respectively. These counts increased steadily to medi-
ans of 351.5 cells/µl (IQR = 225–459.3) and 277.0 cells/
µl (IQR  =  156–451) for KSH and KATH patients 
respectively after the 6  months of HAART administra-
tion. The counts further increased marginally to 374.5 
(IQR = 271.3–535) and 322.5 (IQR = 195–469) and then 
peaked together at 420.0 (IQR =  311–558.5) and 413.5 
(247–552.5) respectively for KATH and KSH. Generally, 
the CD4 counts for KATH subjects were higher than 



























n=214 n=214 n=214 n=201 n=145
Fig. 1 The longitudinal changes of absolute CD4 counts at time 
points of follow ups. The red vertical bars represent the interquartile 
ranges and the midpoints of the bars the medians. The values of “n” 




Fig. 2 a The distribution of absolute CD4 counts for the various age groups. b The gender distribution of the changes in absolute CD4 for males 
(M) and females (F). c The distribution of absolute CD4 counts at the study sites. d The distribution of absolute CD4 counts for subjects with low and 
high baseline CD4 counts. The midpoints of the vertical bars represent the medians and the heights show the interquartile ranges of the absolute 
CD4 counts. The x axes show the time points of follow ups
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those at KSH although the difference was not significant. 
Figure 2c describes the CD4 counts of subjects recorded 
at the two institutions.
The median baseline CD4 counts for low category sub-
jects was 120 (IQR = 48–198) and that for high category 
subjects was 388 (IQR = 305–486). Twelve months after 
baseline HAART administration, the CD4 counts for 
low category subjects increased sharply to a value of 299 
(IQR  =  178–456) while that of high category subjects 
only increased marginally to 420 (IQR = 285–553). After 
12–18  months of HAART administration, the absolute 
CD4 counts plateaued for high category subjects but that 
of low category subjects rose steadily and caught up with 
values of high category subjects at 24 months. Figure 2d 
describes the trajectory of absolute CD4 counts for low 
and high category subjects.
Predictors of rate of absolute CD4 count recovery
There was a general increase in the level of CD4 count 
with time, however this increase significantly slowed 
down with subsequent reviews (p < 0.001). On the aver-
age, the rate of absolute CD4 counts recovery slowed 
down by 28.6 cells/µl for every 6 months of follow up.
Though CD4 counts for persons with low and high 
baseline counts both rose with time the rate of rise was 
significantly slower in those with high baseline compared 
to those with low baseline (difference: 65.7  cell/μl per 
6 months, SE = 12.99, p < 0.001). All other variables were 
not significantly associated with the rate of recovery of 
CD4 counts. Table  2 describes the predictors of rate of 
changes in absolute CD4 counts.
In the final multivariate analysis, significant variables 
such as baseline CD4 counts and time of follow ups were 
included as an interactive term. The results showed that 
the average rate of CD4 count recovery slowed down by 
43.6 cells/µl for every 6 months of follow up (SE = 7.69; 
p < 0.001). Similarly the rate of CD4 count recovery for 
subjects who initiated ARTs with high baseline counts 
was lower than those who started with low baseline CD4 
counts. On the average, the CD4 counts of subjects on 
initial high baseline CD4 counts decreased by 192.6 cells/
µl (SD error = 42.3, p value ≤0.001) for every 6 months 
of follow up compared to those with low baseline CD4 
counts.
Discussion
This study determined retrospectively the association of 
patient-specific factors such as age, gender and socio-
economic status to the immunological response of HIV-
infected patients receiving anti-retroviral therapy at the 
KATH and KSH. The result of the study showed a sus-
tained immune recovery of CD4 counts over time. The 
rate of recovery however slowed down with time. The 
general increase in the absolute CD4 counts corroborate 
other reports about the efficacy of NRTI and NNRTI-
based HAART regimens in HIV-infected patients in 
resource limited countries [17–19].
This study also compared the absolute CD4 counts 
for the different age categories. The overall difference 
was however not significant. Younger age groups have 
however been reported by other authors to have better 
immune CD4 count recovery [20, 21].
An evaluation of the association between HIV 
patient caregiver status and the rate of CD4 count 
recovery did not yield any significant difference. 
A recent study among HIV infected children (age 
0–13  years), reported by Barry et  al. [22], however 
Table 2 Predictors of rate of CD4 count recovery
Predictor Parameter estimate Standard error P value
Intercept 56.7 6.6 <0.001
Time −28.6 6.0 <0.001
Age (years) −0.3 0.7 0.698
Gender
 Female (reference)
 Male −12.3 14.8 0.410
Primary caregiver
Parents (reference)
 Relatives 0.15 14.9 0.992
 Self −17.8 20.1 0.379
 Other −0.3 26.6 0.991
Economic status
 Low (ref )
 Medium 6.4 17.6 0.714
 High −6.0 34.1 0.860
Educational levels
 None (reference)
 Primary −20.4 24.5 0.407
 Secondary −33.1 31.7 0.298
 Tertiary −30.5 27.4 0.267
Place
 KATH (reference)















Low (≤250/µl) (ref )
High (>250/µl) −65.7 13.0 <0.001
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identified having biologic parents as an independent 
factor associated with absolute CD4 count recovery. 
This could possibly mean caregiver status may not play 
any special role in improving CD4 count recovery in 
older children and adults. However our study may not 
have been sufficiently powered to fully evaluate this 
association.
Our study did not find significant association between 
gender and rate of recovery of absolute CD4 counts. The 
relationship between CD4 count recovery and gender 
has received mixed reviews [23–25]. Sempa et  al. [26] 
reported response higher probability of CD4 recovery 
in females compared to males [26]. Teshome and Assefa 
[27] on the other hand did not find significant asso-
ciation in terms of immunological recovery [27]. Our 
result is consistent with the latter report and further 
suggests the need for in-depth investigation into this 
phenomenon.
Our study also revealed greater increases in CD4 
counts for subjects with low baseline CD4 counts over 
the entire duration of the study, compared to subjects 
with high baseline CD4 counts. Other studies have simi-
larly reported long term significant increases in CD4 cell 
counts among subjects with low baseline CD4 counts [28, 
29].
These findings could be due to the redistribution of 
sequestered cells T cells after administration of ARTs 
and the gradual increase of naïve cells because of the 
diminishing antigenic pressure [30]. One limitations of 
this study is the few missing values recorded for some of 
the CD4 count values during follow ups. We also did not 
investigate the influence of resistant strains of HIV in our 
analysis.
In conclusion, our study has shown the effective-
ness of ARTs in improving the recovery of CD4 counts 
over time, particularly for subjects who initiate ther-
apy with low baseline absolute CD4. Future studies 
could explore the role of virological loads and other 
host genetic factors on the recovery of absolute CD4 
counts.
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